Zerodol SP is a combination of aceclofenac, serratiopeptidase and paracetamol.
Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties. It potently inhibits the synthesis of inflammatory mediators that cause pain, swelling, inflammation, and fever. In osteoarthritis and other such conditions, the loss of articular cartilage in the area causes joint pain, tenderness, stiffness, crepitus, and local inflammation. Aceclofenac has high permeability to penetrate into synovial joints thereby reducing the swelling and inflammation of joints.
Serratiopeptidase is an enzyme and has an anti-inflammatory action, analgesic and antipyretic action.
Paracetamol is an analgesic and antipyretic medication used for mild-to-moderate pain and fever.
Zerodol SP is used in following conditions:
Bones and joints pain
Toothache, Ear pain, Headache
Zerodol SP is brand of Ipca, a global pharmaceutical company. Ipca has been partnering healthcare globally in over 120 countries for more than 60 years and in markets as diverse as Africa, Asia, Australia, Europe and the US.
It is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations. The formulations are produced right from the basic stage at manufacturing facilities inspected by the world’s most discerning drug regulatory authorities like US-FDA, UK-MHRA, EDQM-Europe, WHO-Geneva and many more.
Ipca is a therapy leader in India for anti-malarials and has leading brands in 5 therapeutic areas, with 3 of their branded formulations being ranked among the Top-300 Indian brands by ORG-IMS.
Although separate conditions, pain and inflammation are nearly always associated with each other. Pain is defined by the International Association for the Study of Pain (IASP) as ‘an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage’. Inflammation is the tissue’s immunologic response to injury, characterized by mobilization of white blood cells and antibodies, swelling, and fluid accumulation.
There are two basic types of pain: chronic and acute. Acute pain often results from disease, inflammation, or injury to tissues. This type of pain is generally self-limiting; it is confined to a given period of time and severity. In some rare instances, it can become chronic. Chronic pain is widely believed to represent a disease itself. Like pain, inflammation can be both acute and chronic.
Pain of any type is the most frequent reason for physician consultation in the United States, prompting half of all Americans to seek medical care annually. Despite the prevalence of these conditions, the primary options available for their treatment have changed surprisingly little in recent years. Steroids, NSAIDs and opiates are still the mainstay treatments although all have their drawbacks. The search for new analgesics and anti-inflammatory agents is currently the subject of intense drug company interest.
Inflammation in Disease
Chronic persistent inflammation is the cause of many diseases including Alzheimer’s, arthritis, asthma, colitis, irritable bowel syndrome and multiple sclerosis. There are 5 main symptoms of inflammation that are characterized by the Latin words dolor (pain), rubor (redness), tumor (swelling), calor (heat) and functio laesa (loss of function).
Inflammatory diseases are often associated with perturbations to the immune system and an automatic immune response with some exceptions including atherosclerosis.
Potentially Fatal: Paracetamol: Very rare, blood dyscrasias (eg, thrombocytopaenia, leucopaenia, neutropaenia, agranulocytosis); liver damage. Aceclofenac: Severe GI bleeding; nephrotoxicity.
Warnings and Precautions
GI disease; renal or hepatic impairment; alcohol-dependent patients; asthma or allergic disorders; haemorrhagic disorders; hypertension; cardiac impairment. Elderly. Caution when driving or operating machinery. Monitor renal and hepatic function and blood counts during long term treatment. Persistently elevated hepatic enzyme levels may require drug withdrawal. Pregnancy, lactation.
Hypersensitivity. Moderate to severe renal or hepatic impairment; severe heart failure; pregnancy (third trimester).
Paracetamol: Reduced absorption of cholestyramine within 1 hr of administration. Accelerated absorption with metoclopramide. Aceclofenac: M0ay increase the plasma concentrations of lithium and digoxin. Increased nephrotoxicity with diuretics. Serum-potassium should be monitored when used with potassium-sparing diuretics. May enhance activity of anticoagulants. May increase plasma methotrexate levels leading to toxicity if administered within 2-4 hr of methotrexate admin. Risk of convulsions with quinolones.
Potentially Fatal: Paracetamol: Increased risk of liver damage in chronic alcoholics. Increased risk of toxicity with high doses or long term admin of barbiturates, carbamazepine, hydantoins, isoniazid, rifampin and sulfinpyrazone.
Empty stomach promptly by gastric lavage or induction of emesis. Administer standard supportive measures.
Mechanism of Action
Aceclofenac is a phenylacetic acid derivative that inhibits synthesis of the inflammatory cytokines interleukin-1b and tumour necrosis factor, and inhibits prostaglandin E2 production. It increases glycosaminoglycans (GAG) synthesis, the principal macromolecule of the extracellular matrix, which aids in repair and regeneration of articular cartilage. Thus, aceclofenac has +ve effects on cartilage anabolism combined with modulating effect of matrix catabolism. Paracetamol has analgesic and antipyretic action with weak anti-inflammatory activity. It produces analgesia by increasing pain threshold and antipyresis by acting on the hypothalamic heat-regulating centre.